MedGenome Inc. is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases.

Founded in 2013, MedGenome currently has a Next Generation Sequencing (NGS) facility that houses sequencing platforms such as Illumina’s NovaSeq X+ and 6000, and MiSeq, In addition to our wet-lab capabilities, we have built proprietary solutions to enable pharma and biotech companies accelerate their early drug discovery pipeline as well as aid in biomarker discovery for their companion diagnostics programs. Our proprietary cancer immunotherapy solution, OncoPept combines tumor-derived genomic and transcriptomic data to map the molecular features of the tumor and predict personalized cancer immunotherapy combinations with neoantigen vaccines for therapy. MedGenome was awarded the MedTech Breakthrough award for Biomedical research in 2018.

We also support human genetics research by leveraging our extensive infrastructure to access samples and data from patient records through collaborations with over 500 hospitals in India, combined with capabilities to perform population level genomic sequencing of individuals. Through our extensive presence in the Indian sub-continent, we have access to data that provides insights into genetic diversity of Indian population for more than 4,500 population groups. Bioinformatics pipelines built to analyze data from large-scale sequencing efforts will facilitate identifying novel human genetic knockouts and medically relevant variants for drug discovery research.

MedGenome is also founding member of the GenomeAsia 100K, an initiative to sequence 100,000 Genomes in Asia, which will enable us to provide a unique resource of genetic research for the world.

MedGenome Inc. is registered and headquartered in the State of Delaware having its address at 108 West 13th Street City of Wilmington County of New Castle Delaware 19801.